Imugene Ltd - Company Profile
Powered by 
All the data and insights you need on Imugene Ltd in one report.
$295
- Save hours of research time and resources with
our up-to-date Imugene Ltd Strategy Report
- Understand Imugene Ltd position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Imugene Ltd (Imugene) is a clinical-stage biopharmaceutical company that focuses on the development of vaccines in the area of oncology. The company develops immunotherapies that activate the immune system of cancer patients to identify and eradicate tumors. The company develops products for the treatment of various tumors including gastric, breast, lung cancers. Imugene’s lead product candidate, CF33 is a chimeric vaccinia poxvirus for the treatment of mixed advanced solid tumors (MAST) and metastatic triple-negative breast cancer. It develops vaccine candidates based on Mimotope technology, which uses peptide mimics of conformational epitopes recognized by an antibody with antitumor activity. Imugene is headquartered in Sydney, New South Wales Australia.
Headquarters
Australia
Address
Suite 804, Level 8, 37 Bligh Street, Sydney, New South Wales, 2000
Website
www.imugene.com
Telephone
61 3 98245254
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
IMU (ASX)
EPS
XYZ
Net Income (2022)
XYZ
-0.1%
(2022 vs 2021)
Market Cap*
$389.9M
Net Profit Margin (0 vs)
XYZ
0.0%
(2022 vs 2021)
* As of and is in US$
Imugene Ltd premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline |
| azer-cel |
| CF33 + CD19 |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Contracts/Agreements | In December, the company partnered with NeoImmuneTech, Inc. to evaluate Imugene's allogeneic CAR T, azer-cel and NT-I7, for cancer treatment. |
| 2023 | Regulatory Approval | In July, the company secured a Notice of Allowance from the US Patent and Trademark Office (USPTO) for its oncolytic virotherapy CF33. |
| 2023 | Contracts/Agreements | In July, the company and RenovoRx announced a strategic research collaboration to optimize the delivery of Imugene’s oncolytic virus therapy with RenovoRx’s TAMP (Trans-Arterial Micro-Perfusion) therapy platform for the treatment of difficult-to-access tumors. |
Competitor Comparison
| Key Parameters | Imugene Ltd | Rhinomed Ltd | The Sustainable Nutrition Group Ltd | Prescient Therapeutics Ltd | Percheron Therapeutics Ltd |
|---|---|---|---|---|---|
| Headquarters | Australia | Australia | Australia | Australia | Australia |
| City | Sydney | Richmond | South Melbourne | South Melbourne | Melbourne |
| State/Province | New South Wales | Victoria | Victoria | Victoria | Victoria |
| No. of Employees | - | - | 29 | 3 | 8 |
| Entity Type | Public | Private | Private | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Paul Hopper | Chairman | Executive Board | 2012 | - |
| Leslie Chong | Managing Director; Chief Executive Officer | Senior Management | 2018 | - |
| Mike Tonroe | Secretary; Chief Financial Officer | Senior Management | - | - |
| Bradley Glover | Chief Operating Officer | Senior Management | 2023 | - |
| Paul Woodard | Chief Medical Officer | Senior Management | 2023 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer